Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can we map a Tumor's genes fast enough to help patients?

NCT ID NCT03546127

Knowledge-focused Sponsor: Institut National de la Santé Et de la Recherche Médicale, France Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This pilot study tested whether advanced genetic sequencing of tumors can be done quickly enough to guide treatment decisions. Researchers took blood and tumor samples from 24 adults with advanced soft-tissue sarcoma or metastatic colorectal cancer. They measured how long it took to get a complete genetic report back to the doctor. The goal was to see if this process is practical in a real-world hospital setting.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Next Generation Sequencing (genetic testing of tumor and blood samples)
What this could lead to
If successful, this could show that routine genetic profiling of tumors is feasible within a useful timeframe, potentially helping doctors choose more personalized treatments for cancer patients.
What could go wrong
This is a very small pilot study (24 patients) focused only on feasibility and timing, not on whether profiling actually improves patient outcomes. It may not lead to direct treatment benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

24 people

The number who actually took part.

Started

May 2017

Finished

Sep 2017

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients included in this prospective cohort study are patients who have previously consented to tumor sequencing either as part of others studies or as part of standard care (voluntary signed informed consent). Two participating centers have been retained. Samples used (blood and tumor) are issued from these previous collection and analyzed for the same purpose: no additional samples will be collected.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients * Disease: Advanced and/or metastatic soft-tissue sarcoma OR metastatic carcinoma * Patient consenting to tumor sequencing, secondary reuse of their data * Patient informed about this study Exclusion Criteria: * N/A

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colorectal carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

colorectal carcinoma colorectal neoplasm sarcoma soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colorectal carcinoma Soft tissue sarcoma

Contacts and locations

Locations

  • CEA / Centre National de Recherche en Génomique Humaine

    Évry, 91057, France

  • Hôpital Européen Georges Pompidou

    Paris, 75000, France

  • Institut Bergonié

    Bordeaux, 33076, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.